On August 9 2023, OLINK HOLDING AB ($NASDAQ:OLK) reported its earnings results for the second quarter of FY2023, ending June 30 2023. The total revenue for the quarter had a 7.0% year-over-year increase to USD 29.4 million, while the net income was reported as USD -8.3 million, a decrease from the previous year’s -4.8 million.
The company’s stock opened at $15.0 and closed at $15.4, a drop of 5.5% from its last closing price of 16.2. Overall, OLINK HOLDING AB delivered mixed results for the quarter. While revenue saw a modest increase, net income fell due to higher costs.
This resulted in a decrease in earnings per share, which disappointed investors. Moving forward, the company will need to find ways to boost net income in order to sustain the stock price and deliver long-term value to shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for OLK. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for OLK. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for OLK. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for OLK are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – OLK Intrinsic Stock Value
At GoodWhale, we have conducted an analysis of OLINK HOLDING AB’s wellbeing. Our proprietary Valuation Line has calculated the fair value of OLINK HOLDING AB shares to be around $30.6. However, at the time of writing, the stock is currently trading at $15.4 – an undervaluation of 49.7%. This provides a great opportunity for investors to purchase shares at a discount and benefit from the potential upside in the future. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Olink Holding AB and its competitors, Immunovia AB, Genetic Signatures Ltd, and Enzo Biochem Inc, is fierce as each company strives to stay ahead of the game and provide innovative solutions in the healthcare industry. With each company striving to become a leader in the field, the competition is sure to be an exciting one.
Immunovia AB is a Swedish-based biotechnology company that develops and markets diagnostic tests for the early detection of cancer and autoimmune diseases. The company’s flagship product, IMMray PanCan-d, is a blood test that is designed to detect the early signs of pancreatic cancer. As of 2023, Immunovia AB has a market capitalization of 173.13 million, which indicates the company’s size and value in the public markets. Despite its size and potential, Immunovia AB has a negative return on equity of -29.26%, which suggests that it is not generating positive cash flows or returns to its shareholders.
– Genetic Signatures Ltd ($ASX:GSS)
Genetic Signatures Ltd is a biotechnology company focused on the development and commercialization of molecular diagnostic tests. With a market cap of 122.61M as of 2023, the company has seen a respectable level of growth over the past few years. Their Return on Equity (ROE) stands at -10.13%, indicating that their current shareholders are not seeing much in terms of returns on their investments. This could be due to a number of factors, including the fact that the company is still relatively new and is in the early stages of its growth.
– Enzo Biochem Inc ($NYSE:ENZ)
Enzo Biochem Inc is a biotechnology company based in Farmingdale, New York. It is engaged in the research, development, production and marketing of diagnostic and research products based on molecular biology and genetic engineering techniques. As of 2023, the company has a market cap of 53.59M and a Return on Equity of -29.91%. Market cap is an indicator of the size and value of a company, representing the total market value of its outstanding shares. As of 2023, Enzo Biochem Inc has a relatively small market cap compared to other larger biotechnology companies. On the other hand, Return on Equity (ROE) is a measure of profitability that shows how much profit the company generates from its shareholders’ equity. Enzo Biochem Inc has an unfavorable ROE of -29.91%, which means the company is not generating a profit for its investors.
OLINK HOLDING AB released its second quarter earnings report for FY2023, with total revenue increasing 7.0% year-over-year to USD 29.4 million. Although net income decreased to USD -8.3 million, compared to the previous year’s -4.8 million, stock price still dropped on the same day. Investors are likely cautious due to the decline in net income and may need more details and information on how the company plans to improve profitability. Further analysis into the company’s performance and financials could help investors discern whether to invest or not in OLINK HOLDING AB.